CTIS2023-503228-17-00进行中（未招募）1 期
Combining intratumoral flu vaccine and systemic pembrolizumab in patients with early pMMR colorectal cancer – the FLU-IMMUNE trial.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Have histologically confirmed localized pMMR stage cT1N0M0 to cT4N2M0 (stage I to III) colorectal carcinoma., Participants must use (or have their partner use) an acceptable method of contraception, during heterosexual activity, while receiving pembrolizumab and for 120 days after the administration., Women of reproductive potential (WORP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to receiving pembrolizumab., Women must not be breastfeeding., Have indication for elective curative intended surgery without neoadjuvant chemotherapy., Be = 18 years of age on the date of signing the informed consent., Provide written informed consent, Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1., Have adequate bone marrow function: Hemoglobin = 6.2 mmol/L or = 10 g/dL Absolute neutrophil count (ANC) = 1.5 × 109/L Platelet count = 100 × 109/L, Have adequate kidney function defined as Glomerular filtration rate (GFR) = 60 mL/min or creatinine =1.5 X upper limit of normal (ULN), Have adequate liver function defined as: Total bilirubin = 1.5 × ULN Alanine aminotransferase (ALT): = 2.5 × ULN Alkaline phosphatase: = 2.5 × ULN, Follow the conditions regarding fertility, pregnancy, and lactation: Female and male participants of reproductive potential (for definition refer to appendix 18) must agree to avoid becoming pregnant or impregnating a partner, respectively, while receiving pembrolizumab and for 120 days after the administration.
排除标准
- •Has any serious or uncontrolled medical disorder that, in the opinion of the investigator or treating physician, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results., Acute febrile illness, Acute infectious disease, Highly inflamed gastrointestinal tissue which is ulcerated and bleeding, Has an autoimmune disorder (except thyroiditis with replacement therapy and type I diabetes mellitus)., Has received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody or any other antibody/drug specifically targeting T cell co-stimulation or checkpoint pathways., Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active chronic or acute Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA is detected)., Has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease., Has received live vaccines within 30 days prior to first dose trial treatment (Examples of live vaccines include, but are not limited to: measles, mumps, rubella, chickenpox), Has recently received yellow fever, rabies, BCG, and typhoid (oral) vaccine., Has a history of allergy to study drug components or a history of severe hypersensitivity reaction to any monoclonal antibody, Any previous allergic reaction to influenza vaccine or constituents, egg and chicken proteins, neomycin, formaldehyde or octoxinol-9
研究者
相似试验
尚未招募
不适用
Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC)on Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000270Center of Molecular Immunology (CIM)30
已完成
1 期
Combination therapy of the peptide vaccines and dexamethasone for hormone-refractory prostate cancer: Early phase II randomized controlled studyProgressive hormone-refractory prostate cancerJPRN-UMIN000000959Department of Urology, Kinki University School of Medicine100
尚未招募
2 期
Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal CancerColorectal CancerNCT05909423Zealand University Hospital21
进行中（未招募）
1 期
Intratumoral Influenza Vaccine for Early Colorectal CancerPatients with colorectal cancerMedDRA version: 21.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10010032Term: Colorectal cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10010033Term: Colorectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10010034Term: Colorectal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000725-27-DKCenter for Surgical Science, Department of Surgery, Zealand University Hospital30
进行中（未招募）
不适用
Peptide-based vaccine in combination or not with chemotherapy in melanoma patients: a phase II randomized clinical study. - NDMedDRA version: 12.0Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)advanced melanomaEUCTR2008-008211-26-ITISTITUTO SUPERIORE DI SANITA`